Moderna partners with Swiss firm Lonza to produce potential coronavirus vaccine

Moderna, the Cambridge drug company whose experimental vaccine for the novel coronavirus was first in the United States to make it to clinical trials, has partnered with Swiss drug maker Lonza to manufacture up to 1 billion doses a year of the potential vaccine ― should it be approved by regulators ― the companies announced Friday. Read the full article By Jeremy C. Fox, Globe Correspondent on www.bostonglobe.com